Literature DB >> 15867791

Adenosine A2A receptor activation reduces inflammation and preserves pulmonary function in an in vivo model of lung transplantation.

T Brett Reece1, Peter I Ellman, Thomas S Maxey, Ivan K Crosby, Patrick S Warren, Tae W Chong, Robin D LeGallo, Joel Linden, John A Kern, Curtis G Tribble, Irving L Kron.   

Abstract

BACKGROUND: Reperfusion injury continues to significantly affect patients undergoing lung transplantation. Isolated lung models have demonstrated that adenosine A 2A receptor activation preserves function while decreasing inflammation. We hypothesized that adenosine A 2A receptor activation by ATL-146e during the initial reperfusion period preserves pulmonary function and attenuates inflammation in a porcine model of lung transplantation.
METHODS: Mature pig lungs preserved with Viaspan (Barr Laboratories, Pomona, NY) underwent 6 hours of cold ischemia before transplantation and 4 hours of reperfusion. Animals were treated with (ATL group, n = 7) and without (IR group, n = 7) ATL-146e (0.05 microg kg -1 . min -1 ATL-146e administered intravenously for 3 hours). With occlusion of the opposite pulmonary artery, the animal was maintained for the final 30 minutes on the allograft alone. Recipient lung physiology was monitored before tissue evaluation of pulmonary edema (wet-to-dry weight ratio), myeloperoxidase assay, and tissue tumor necrosis factor alpha by means of enzyme-linked immunosorbent assay.
RESULTS: When the ATL group was compared with the IR group, the ATL group had better partial pressure of carbon dioxide (43.8 +/- 4.1 vs 68.9 +/- 6.3 mm Hg, P < .01) and partial pressure of oxygen (272.3 +/- 132.7 vs 100.1 +/- 21.4 mm Hg, P < .01). ATL-146e-treated animals exhibited lower pulmonary artery pressures (33.6 +/- 2.1 vs 47.9 +/- 3.5 mm Hg, P < .01) and mean airway pressures (16.25 +/- 0.08 vs 16.64 +/- 0.15 mm Hg, P = .04). ATL-146e-treated lungs had lower wet-to-dry ratios (5.9 +/- 0.39 vs 7.3 +/- 0.38, P < .02), lower myeloperoxidase levels (2.9 x 10 -5 +/- 1.2 x 10 -5 vs 1.3 x 10 -4 +/- 4.0 x 10 -5 DeltaOD mg -1 . min -1 , P = .03), and a trend toward decreased lung tumor necrosis factor alpha levels (57 +/- 12 vs 96 +/- 15 pg/mL, P = .06). The ATL group demonstrated significantly less inflammation on histology.
CONCLUSION: Adenosine A 2A activation during early reperfusion attenuated lung inflammation and preserved pulmonary function in this model of lung transplantation. ATL-146e and similar compounds could play a significant role in improving outcomes of pulmonary transplantation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15867791     DOI: 10.1016/j.jtcvs.2004.11.042

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  31 in total

Review 1.  Adenosine signaling and the regulation of chronic lung disease.

Authors:  Yang Zhou; Daniel J Schneider; Michael R Blackburn
Journal:  Pharmacol Ther       Date:  2009-05-05       Impact factor: 12.310

2.  Airway pressure release ventilation during ex vivo lung perfusion attenuates injury.

Authors:  J Hunter Mehaffey; Eric J Charles; Ashish K Sharma; Dustin T Money; Yunge Zhao; Mark H Stoler; Christine L Lau; Curtis G Tribble; Victor E Laubach; Mark E Roeser; Irving L Kron
Journal:  J Thorac Cardiovasc Surg       Date:  2016-09-22       Impact factor: 5.209

3.  Adenosine A₂A agonist improves lung function during ex vivo lung perfusion.

Authors:  Abbas Emaminia; Damien J Lapar; Yunge Zhao; John F Steidle; David A Harris; Victor E Laubach; Joel Linden; Irving L Kron; Christine L Lau
Journal:  Ann Thorac Surg       Date:  2011-10-31       Impact factor: 4.330

4.  Pretreatment strategy with adenosine A2A receptor agonist attenuates reperfusion injury in a preclinical porcine lung transplantation model.

Authors:  Damien J LaPar; Victor E Laubach; Abbas Emaminia; Ivan K Crosby; Vanessa A Hajzus; Ashish K Sharma; Heather M Sumner; David V Webb; Christine L Lau; Irving L Kron
Journal:  J Thorac Cardiovasc Surg       Date:  2011-07-16       Impact factor: 5.209

5.  Activation of A1, A2A, or A3 adenosine receptors attenuates lung ischemia-reperfusion injury.

Authors:  Leo M Gazoni; Dustin M Walters; Eric B Unger; Joel Linden; Irving L Kron; Victor E Laubach
Journal:  J Thorac Cardiovasc Surg       Date:  2010-04-15       Impact factor: 5.209

6.  Ecto-5'-nucleotidase (CD73) attenuates allograft airway rejection through adenosine 2A receptor stimulation.

Authors:  Takashi Ohtsuka; Paul S Changelian; Diane Bouïs; Kathleen Noon; Hiroaki Harada; Vibha N Lama; David J Pinsky
Journal:  J Immunol       Date:  2010-06-14       Impact factor: 5.422

Review 7.  Targeting of adenosine receptors in ischemia-reperfusion injury.

Authors:  Victor E Laubach; Brent A French; Mark D Okusa
Journal:  Expert Opin Ther Targets       Date:  2010-11-29       Impact factor: 6.902

Review 8.  A2A receptors in inflammation and injury: lessons learned from transgenic animals.

Authors:  György Haskó; Pál Pacher
Journal:  J Leukoc Biol       Date:  2007-12-26       Impact factor: 4.962

9.  Ex vivo lung perfusion with adenosine A2A receptor agonist allows prolonged cold preservation of lungs donated after cardiac death.

Authors:  Cynthia E Wagner; Nicolas H Pope; Eric J Charles; Mary E Huerter; Ashish K Sharma; Morgan D Salmon; Benjamin T Carter; Mark H Stoler; Christine L Lau; Victor E Laubach; Irving L Kron
Journal:  J Thorac Cardiovasc Surg       Date:  2015-07-30       Impact factor: 5.209

10.  Early adenosine receptor activation ameliorates spinal cord reperfusion injury.

Authors:  T Brett Reece; Curtis G Tribble; David O Okonkwo; Jonathon D Davis; Thomas S Maxey; Leo M Gazoni; Joel Linden; Irving L Kron; John A Kern
Journal:  J Cardiovasc Med (Hagerstown)       Date:  2008-04       Impact factor: 2.160

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.